Navigation Links
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Date:9/22/2007

. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme(R) and Campath(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-703-797-1866 outside the United States.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

For more information about Campath, including full prescribing information, call 1-888-84-BAYER (1-888-842-2937) or visit http://www.campath.com.

This press release contains forward-loo
'/>"/>

SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. FDA Approves Contraceptive Ring
3. FDA approves new device to treat womens bleeding disorder
4. FDA Approves New HIV Drug, Viread
5. FDA Approves Birth Control Skin Patch
6. FDA approves surgical gel
7. FDA Approves New Arthritis Drug, Bextra
8. FDA Approves Elidel Cream for Eczema
9. FDA approves drug for rare liver disease
10. FDA approves first pocket-sized EKG machine
11. FDA Approves New Anti-Clotting Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...earchers who pioneered treatments which have helpe... other autoimmune diseases have been awarded the p...cal Research, announced today. , Emeritus Profes..., who have been carrying out research together at ...cted for the $100K award by an international commi...
(Date:5/12/2008)...Bermuda and COPENHAGEN, Denmark, May 12,/PRNewswir...ounced today,that the United States Food and Drug ...lication (NDA) for Taclonex Scalp(R) (calcipotrien...pical Suspension. LEO Pharma submitted,the NDA for...ex Scalp(R) is,a topical suspension containing a c...
(Date:5/12/2008)... Calif., May 12 /PRNewswire/ -- Emphasys Medical I...ENT clinical trial of the,company,s Zephyr(R) Endo...ernational Conference of the American Thoracic Soc...da., Sunday, May 18, 9:30-11:00 a.m. (ET), Metro ...osium, "Innovations in Emphysema Treatment: Lung V...
(Date:5/12/2008)...y 12 /PRNewswire-FirstCall/ -- Allied Healthcare P... its net income for the third,quarter ending March..., or,4 cents per share, to about $100,000 in the c...he third quarter increased by about $240,000 compa...r, higher material and labor costs,this fiscal yea...
Breaking Medicine News(10 mins):Health News:Researchers who helped millions with arthritis receive prestigious Janssen Award 2Health News:Researchers who helped millions with arthritis receive prestigious Janssen Award 3Health News:Researchers who helped millions with arthritis receive prestigious Janssen Award 4Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 2Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 3Health News:FDA Approves Taclonex Scalp(R) - Once Daily Therapy for Treatment of Moderate to Severe Scalp Psoriasis 4Health News:Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 3Health News:Allied Healthcare Net Falls on Manufacturing Delays 4Health News:Allied Healthcare Net Falls on Manufacturing Delays 5
... sugar cane disease the Queensland Department of P...r // Childers, south-west of Bundaberg. Although ... it claims that the potential effects could be ser...ecurity, Chris Adriaansen, has stated that DPI off...
...hikode Medical College Hospital, Kerala they remov...’s stomach //. The man named Akkooppoyil Achuthan...val of a six Kg tumor. Then he was discharged but...al complaining acute pain symptoms. After an X-ra...
...ternational Diabetes Federation (IDF) the last 20 ...betes worldwide having risen from 30 million to 23... now have the most diabetes sufferers in the world...eyed countries, China and India amount for the mos...
...have a neurobiological side to it. A new study sug...Erritzoe and his colleagues at Copenhagen Universi...eople of normal weight and 29 overweight people. T...people have more receptors for the neurotransmitte...
Other Medicine News:Health News:Diabetes On A Steady Alarming Rise From The Past 20 Years 2
(Date:5/9/2008)...s Following Bunionectomy,, TAMPA, Fla., May 9 ...nts experience intense pain for several days follo...oot surgeries. The investigational pain,medication...ts who had this,surgery, compared to those treated...lted in patients reporting fewer gastrointestinal ...
(Date:5/9/2008).../ -- Ardea Biosciences, Inc.,(Nasdaq: RDEA ), a c...,small- molecule therapeutics for the treatment of...gout, today announced that John W. Beck,has been a...ions and Chief,Financial Officer effective May 27,...shortly thereafter. The Company also reported rece...
(Date:5/9/2008)...ows Positive Results with X-ray ...wire/ -- Roche today announced one-year,results fr...EMRA(TM),(tocilizumab) can significantly inhibit p...nts with rheumatoid arthritis (RA), a critical mea...y also demonstrated that ACTEMRA,reduces disease s...
(Date:5/8/2008).../ -- DATATRAK International, Inc.,(Nasdaq: DATA )...bal,eClinical solutions for the clinical trials in...he first quarter of 2008., For the three months e...ly 41% to $2,088,000 and the Company reported a ne...th a basic and diluted basis. These,results compar...
Breaking Medicine Technology:New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 2New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 3New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 4New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7New Benefactors Show Support for CDA4CDT 3A 2638 1New Benefactors Show Support for CDA4CDT 3A 2638 2New Benefactors Show Support for CDA4CDT 3A 2638 3New Benefactors Show Support for CDA4CDT 3A 2638 4New Benefactors Show Support for CDA4CDT 3A 2638 5New Benefactors Show Support for CDA4CDT 3A 2638 6New Benefactors Show Support for CDA4CDT 3A 2638 7Angiotech and Symphony Medical Announce Licensing Agreement 2636 1Angiotech and Symphony Medical Announce Licensing Agreement 2636 2Angiotech and Symphony Medical Announce Licensing Agreement 2636 3Angiotech and Symphony Medical Announce Licensing Agreement 2636 4Angiotech and Symphony Medical Announce Licensing Agreement 2636 5Angiotech and Symphony Medical Announce Licensing Agreement 2636 6Newly discovered virus linked to deadly skin cancer 9721 1Newly discovered virus linked to deadly skin cancer 9721 2Newly discovered virus linked to deadly skin cancer 9721 3Newly discovered virus linked to deadly skin cancer 9721 4Scripps research scientists find new genetic mutation that halts the development of lupus 9720 1Scripps research scientists find new genetic mutation that halts the development of lupus 9720 2Scripps research scientists find new genetic mutation that halts the development of lupus 9720 3
...ND OAKS, Calif. & COLLEGEVILLE, Pa.--(BUSINESS...th Pharmaceuticals, a,division of Wyeth (NYSE:WYE)...ata that showed that the safety profile of Enbrel(...in patients with,moderate-to-severe juvenile rheum...ars of therapy. JRA is a chronic autoimmune,diseas...
...inical Studies Show 227Th-rituximab More Effective...tiuxetan-ibritumomab,(Zevalin) , OSLO, Norway, 14 ...n cancer therapeutics company, announces that a re...hnology for targeted,cancer therapy has been publi...ficial journal of the American Society of Hematolo...
Other Medicine Technology:Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 2Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 3Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 4Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 5Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 6Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 7Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 8Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood 2Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood 3Algeta Demonstrates Targeted Cancer-killing Potential of Novel,Alpha Particle Linked Antibodies in Leading Medical Journal Blood 4
Each handle is designed to fit a specific trephine size.
Each handle is designed to fit a specific trephine size.
Reusable, stainless steel trephine with handle.
Reusable, stainless steel trephine with handle.
Medicine Products: